Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8025998 | 1.00 | CYP2C9 (0.65) | CYP2C9ALDH1A1TSHRMAPTPDCD1 | |
| SCHEMBL1680433 | 1.00 | CYP2C9 (0.65) | CYP2C9ALDH1A1TSHRMAPTPDCD1 | |
| SCHEMBL9544480 | 0.98 | CYP2C9 (0.62) | CYP2C9ALDH1A1TSHRMAPTPDCD1 | |
| SCHEMBL8027195 | 0.98 | CYP2C9 (0.62) | CYP2C9ALDH1A1TSHRMAPTPDCD1 | |
| SCHEMBL8027197 | 0.98 | CYP2C9 (0.62) | CYP2C9ALDH1A1TSHRMAPTPDCD1 | |
| SCHEMBL9544475 | 0.98 | CYP2C9 (0.62) | CYP2C9ALDH1A1TSHRMAPTPDCD1 | |
| SCHEMBL4906704 | 0.87 | CYP2C9 (0.69) | CYP2C9ALDH1A1TSHRMAPTPDCD1 | |
| SCHEMBL4961560 | 0.87 | CYP2C9 (0.69) | CYP2C9ALDH1A1TSHRMAPTPDCD1 | |
| SCHEMBL2755215 | 0.87 | CYP2C9 (0.69) | CYP2C9ALDH1A1TSHRMAPTPDCD1 | |
| SCHEMBL19355063 | 0.83 | CYP2C9 (0.65) | CYP2C9ALDH1A1TSHRMAPTPDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106111189-B | A kind of chirality pyridoxamine catalyst and its synthetic method and application | 上海师范大学 | 2019-03-08 | — | — | CN | disclosed |
| CN-106111189-A | A kind of chirality pyridoxamine catalyst and synthetic method thereof and application | 上海师范大学 | 2016-11-16 | — | — | CN | disclosed |
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| US-7932272-B2 | Antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090227799-A1 | Novel Antimalarial Agent Containing Heterocyclic Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1782811-A1 | NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| EP-1211556-B1 | Thermally developable imaging materials containing surface barrier layer | EASTMAN KODAK CO (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1246002-A2 | Thermally developable imaging materials containing polyester polymeric barrier layer | EASTMAN KODAK COMPANY (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1213609-A2 | High contrast thermally-developable imaging materials containing barrier layer | EASTMAN KODAK COMPANY (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1211556-A2 | Thermally developable imaging materials containing surface barrier layer | EASTMAN KODAK COMPANY (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6352820-B1 | MATERIAL COMPRISING SUPPORT BEARING THERMALLY DEVELOPABLE IMAGING LAYER COMPRISING BINDER, NON-PHOTOSENSITIVE SOURCE OF REDUCIBLE SILVER IONS AND REDUCING AGENT, BARRIER LAYER COMPRISING FILM-FORMING, WATER-INSOLUBLE AROMATIC POLYESTER | EASTMAN KODAK COMPANY | 2002-03-05 | — | — | US | disclosed |
| US-6352819-B1 | MATERIAL COMPRISING SUPPORT, THERMALLY-DEVELOPABLE IMAGING LAYER COMPRISING BINDER, PHOTOSENSITIVE SILVER HALIDE, SOURCE OF REDUCIBLE SILVER IONS, REDUCING AGENT AND HIGH CONTRAST AGENT, AND BARRIER LAYER COMPRISING FILM FORMING POLYMER | EASTMAN KODAK COMPANY | 2002-03-05 | — | — | US | disclosed |
| US-6350561-B1 | Thermally developable imaging materials containing surface barrier layer | EASTMAN KODAK COMPANY | 2002-02-26 | — | — | US | disclosed |
| EP-0852026-B1 | BLACK-AND-WHITE PHOTOTHERMOGRAPHIC AND THERMOGRAPHIC ELEMENTS COMPRISING ACRYLONITRILE COMPOUNDS AS CO-DEVELOPERS | EASTMAN KODAK CO (US) | 2000-03-01 | — | — | EP | disclosed |
| EP-0852026-A1 | BLACK-AND-WHITE PHOTOTHERMOGRAPHIC AND THERMOGRAPHIC ELEMENTS COMPRISING ACRYLONITRILE COMPOUNDS AS CO-DEVELOPERS | Imation Corp. (US) | 1998-07-08 | — | — | EP | disclosed |
| WO-1997011409-A1 | BLACK-AND-WHITE PHOTOTHERMOGRAPHIC AND THERMOGRAPHIC ELEMENTS COMPRISING ACRYLONITRILE COMPOUNDS AS CO-DEVELOPERS | IMATION CORP. (US) | 1997-03-27 | — | — | WO | disclosed |
| US-5545515-A | ELEMENT CONTAINING SILVER REDUCING AGENT SYSTEM INCLUDING HINDERED PHENOL AND ACRYLONITRILE COMPOUND | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | ERG28, CYP51A1, XPO1 | CYP2C9 1072/4885ALDH1A1 1677/4885TSHR 3875/4885 |
| US-20090227799-A1 | Novel Antimalarial Agent Containing Heterocyclic Compound | XPO1, THPO, G6PD | CYP2C9 3419/4885ALDH1A1 1926/4885TSHR 3836/4885 |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | ERG28, DPM1, CYP51A1 | CYP2C9 1154/4885ALDH1A1 1459/4885TSHR 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.